NSE: TTKHLTCARE · BSE: 507747
TTK HEALTHCARE LIMITED
Operates a diversified portfolio across five business segments, generating Rs. 857.28 cr of revenue in FY26. Consumer Products contributed 28.1% of segment revenue (Rs. 241.28 cr, 7.6% EBIT margin); the board has approved the sale of the EVA and Good Home brands in this segment to Wipro Enterprises for Rs. 256 crores plus GST, with these brands accounting for roughly Rs. 148 crores (about 17% of turnover). Protective Devices, at 25.3% of revenue (Rs. 216.51 cr), posted a negative EBIT margin of -4.9% on the loss of USAID institutional business. Foods (17.6%, Rs. 151.10 cr) and Animal Welfare (16.5%, Rs. 141.08 cr) each delivered EBIT margins above 8%. Medical Devices was the smallest segment at 12.5% (Rs. 106.92 cr) but the most profitable with a 21.1% EBIT margin. The company runs 8 manufacturing plants and 41 offices in India, employs 1,259 staff alongside 2,374 workers, and exports to 28 countries; male contraceptives, food products and animal welfare items are the largest product categories. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Consumer Products (28%), Protective Devices (25%), Foods (18%), Animal Welfare (17%), Medical Devices (13%), Others (0%). Diversified consumer healthcare and products group across five distinct segments.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 599 | 725 | 753 | 801 | 857 |
| EBITDA (ex other income) | 24 | 31 | 37 | 49 | 22 |
| margin % | 4.1 | 4.3 | 5.0 | 6.1 | 2.6 |
| Owners' profit | 42 | 640 | 63 | 82 | 66 |
| EPS, as reported (₹) | 29.43 | 452.72 | 44.47 | 57.79 | 46.48 |
| ROE % · ROCE % | 12.6 · 7.8 | 67.1 · 7.0 | 6.3 · 8.6 | 7.7 · 10.4 | 5.9 · 7.6 |
| Debt / equity (x) | 0.06 | 0.03 | 0.02 | 0.02 | 0.02 |
| Cash from operations | 45 | (26) | (5) | (4) | (21) |
| Capex | (6) | (12) | (10) | (13) | (6) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 198 | 205 | 190 | 226 | 204 | 209 | 218 | 258 |
| Profit before tax | 23 | 23 | 22 | 18 | 21 | 14 | 30 | 29 |
| Net profit | 17 | 17 | 16 | 13 | 20 | 11 | 22 | 21 |
| EPS (₹) | 12.17 | 11.84 | 11.43 | 9.20 | 14.43 | 7.45 | 15.40 | 15.06 |
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Animal Welfare | 103 | 12.0 |
| Consumer Products | 186 | 21.7 |
| Medical Devices | 81 | 9.5 |
| Protective Devices | 163 | 19.0 |
| Foods | 115 | 13.4 |
| Others | 0 | 0.0 |
| ANIMAL WELFARE | 38 | 4.4 |
| CONSUMER PRODUCTS | 55 | 6.5 |
| MEDICAL DEVICES | 26 | 3.0 |
| PROTECTIVE DEVICES | 54 | 6.3 |
| FOODS | 36 | 4.2 |
| OTHERS | 0 | 0.0 |
| Total, before eliminations | 857 | 100.0 |
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| 3M INDIA LIMITED | 32,491 | 53.1 | 15.13 | 37.5 | 27.2 | 35.7 | 6.8 | 21.7 |
| GODREJ INDUSTRIES LTD | 31,855 | 27.1 | 1.37 | 13.5 | 10.4 | 6.4 | 19.0 | 27.3 |
| DCM SHRIRAM LIMITED | 14,235 | 9.8 | 1.84 | 10.0 | 11.1 | 9.5 | 11.4 | 11.7 |
| KAMA HOLDINGS LTD. | 6,790 | 7.3 | 0.45 | — | 12.3 | — | 13.5 | 22.4 |
| BALMER LAWRIE & CO LTD | 2,647 | 9.5 | 1.27 | 6.8 | 13.0 | 11.2 | 12.2 | 14.8 |
| TTK HEALTHCARE LIMITED ◆ | 1,448 | 19.6 | 1.30 | — | 5.9 | 7.4 | — | 12.2 |
| EMPIRE INDUSTRIES LTD. | 563 | 10.9 | 1.60 | — | 14.7 | 10.5 | — | 19.5 |
| GILLANDERS ARBUTHNOT LTD | 203 | 11.6 | 0.79 | 10.0 | 3.7 | 3.5 | 0.0 | 9.0 |
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 19.6 | 11.5 | 12 of 15 | 21% |
| P/B | 1.3 | 1.1 | 9 of 14 | 31% |
| ROCE | 7.4 | 8.4 | 8 of 14 | 46% |
| ROE | 5.9 | 10.7 | 11 of 14 | 23% |
| Debt / Equity | 0.0 | 0.4 | 3 of 13 | 83% |
| EBITDA margin | 12.2 | 20.6 | 11 of 14 | 23% |
| Revenue growth | 13.8 | 11.9 | 7 of 14 | 54% |
| Profit growth | 63.7 | 100.4 | 9 of 13 | 33% |
| Market cap | 1448 | 203 | 6 of 15 | 64% |
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 23 Oct 2026 · TTK Healthcare board to approve September quarter results on October 30 | results | low | — | — |
| 12 Oct 2026 · Routine filing of demat certificate under SEBI Reg 74(5) for Q2 FY27 | compliance | minimal | — | — |
| 22 Sept 2026 · Trading Window Closure Ahead of Q2 FY26-27 Results | compliance | minimal | — | — |
| 4 Sept 2026 · TTK Healthcare completes sale of EVA and Good Home brands to Wipro Enterprises | strategic transactions | high | — | — |
| 2 Sept 2026 · TTK Healthcare appoints R V K and Co as Tax Auditor for 3 years | management changes | medium | — | — |
| 27 Aug 2026 · Tax Auditor M/s Aiyar & Co. withdraws from FY 2025-26 assignment | management changes | medium | — | — |
| 27 Aug 2026 · Filing of newspaper notice on physical share demat window | compliance | minimal | — | — |
| 6 Aug 2026 · Q1 PAT up 64%, inks Rs.256 cr brand sale deal with Wipro | results | high | — | — |
| 6 Aug 2026 · Q1 FY27 PAT up 64% YoY at Rs 21.3 cr; Rs 256 cr brand sale to Wipro | results | high | — | — |
| 27 Jul 2026 · TTK Healthcare Board Meeting on Aug 6 to Consider Q1 FY27 Results | results | low | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.